Safety analysis of simultaneous administration of diphtheria，tetanus and acellular pertussis combined vaccine and group A and C meningococcal polysaccharide vaccine among 6-year-old children in Quanzhou City
10.16835/j.cnki.1000-9817.2026243
- VernacularTitle:泉州市6岁儿童吸附无细胞百白破联合疫苗与A群C群流脑多糖疫苗同时接种安全性分析
- Author:
HUANG Caihong, ZHAN Huichun, CHEN Yahong, ZHANG Lingling
1
Author Information
1. Department of Immunization Program, Quanzhou Center for Disease Control and Prevention (Quanzhou Municipal Health Inspection Institute) , Quanzhou 362000, Fujian Province, China
- Publication Type:Journal Article
- Keywords:
Diphtheria,tetanus and pertussis combined vaccine,adsorbed；Epidemic meningitis A, C polysaccharide vaccine；Vaccination；Child
- From:
Chinese Journal of School Health
2026;47(8):1198-1202
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of the simultaneous administration of diphtheria, tetanus and acellular pertussis combined vaccine (DTaP) and group A and C meningococcal polysaccharide vaccine (MPSV-AC), so as to provide a scientific reference for vaccination strategies among school age children.
Methods:Vaccination data and adverse reaction data for 2025 were collected from the Fujian Provincial Immunization Program Information Management System and the National Immunization Program Information System. The Chi-square test and Poisson regression model were used to compare the risk of adverse reactions between concurrent and separate vaccination.
Results:In 2025, a total of 90 854 doses of DTaP were administered to children who turned 6 years old, with 107 adverse reactions reported, yielding an adverse reaction reporting rate of 117.77 per 100 000. A total of 95 913 doses of MPSV-AC were administered, with 50 adverse reactions reported, yielding an adverse reaction reporting rate of 52.13 per 100 000. All adverse reactions following DTaP and MPSV-AC vaccination in children were common reactions, predominantly local redness, swelling, and induration, with no reported abnormal reactions. The reported rate of common reactions was 112.91 per 100 000 in the concurrent DTaP+MPSV-AC group; in the separate groups, the reported rates of common reactions were 120.75 per 100 000 for DTaP and 17.92 per 100 000 for MPSV-AC, with statistically significant difference ( χ 2=46.23, P < 0.01 ). The risk of common adverse reactions in the simultaneous vaccination group did not differ significantly from that in the DTaP only group ( RR =1.07, P =0.74), but was significantly lower than that in the MPSV-AC only group ( RR =0.16, P <0.01). The risks of fever (11.58 per 100 000), pruritus, rash, myalgia, gastrointestinal symptoms, and other symptoms (23.16 per 100 000) in the simultaneous vaccination group were not significantly different from those in either single vaccine group ( RR-DTaP =0.92, 1.84, RR-MPSV-AC =0.56, 0.35, both P >0.05). The two most frequently reported reactions in both the simultaneous vaccination and DTaP only groups were local redness/swelling (95.54 per 100 000 and 117.20 per 100 000) and induration (31.85 per 100 000 and 42.62 per 100 000) at the injection site. In the simultaneous vaccination group, 92.50% of clinical symptoms occurred within 48 h, and the risks of occurrence at <24 h, 24-<48 h , and ≥48 h were not significantly different from those in the DTaP only group ( RR =1.00, 0.98, 1.43, all P >0.05).
Conclusion:The simultaneous administration of DTaP and MPSV-AC does not increase the risk of adverse reactions and may serve as a reference for administering both vaccines concurrently in children aged 6 years.
